Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 115,059 restricted stock units of Atara's common stock to 13 newly hired employees and stock options to purchase an aggregate of 118,745 shares of Atara's common stock to eight such newly hired employees. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of May 2, 2022, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options have a ten-year term and an exercise price of $6.94 per share, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 2, 2022.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.


These press releases may also interest you

at 19:30
Allied Market Research recently published a report, titled, "Public Safety and Security Market by Offering (Solution, Service), by Enterprise Size (Large Enterprises, SMEs), by Application (Emergency Communication and Incident Management,...

at 19:10
Wolters Kluwer Finance, Risk & Regulatory Reporting (FRR) presents a CFO Roundtable discussion in August for finance leaders and other senior decision makers in banking and financial services that explores the future of regulatory compliance in...

at 18:35
Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") , a developer and retailer of cutting-edge eyeglasses and sunglasses designed to allow the users to remain connected to their digital lives, today announced the pricing of its initial...

at 11:00
SEO Company, SEO.co is pleased to announce the release of the company's latest guide, which outlines the top 200 Google ranking factors for SEO in 2022. The company's newly released guide outlines 200 of the 2,000+ factors scanned that are currently...

at 08:00
xTool, an up-and-running laser engraving machine brand, partner with Pencils of Promise for back-to-school season. Pencils of Promise (PoP) builds safe and healthy public primary school environments, with well-trained and supported teachers, where...

at 01:00
Alpine Media, the next-generation ski resort guest engagement and communication platform to roll out three groundbreaking mobile services to redefine the ski resort experience. The convenience and ease of mobile eCommerce is now climbing up Colorado...



News published on 6 may 2022 at 16:05 and distributed by: